Please login to the form below
infectious diseases
This page shows the latest infectious diseases news and features for those working in and with pharma, biotech and healthcare.
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19
The ACTT-2 trial, which was sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID), evaluated a 4mg dose of Olumiant (baricitinib) given alongside remdesivir versus remdesivir alone
Latest news
-
GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2
We have observed promising early-stage results showing antiviral activity with our anti-sense oligonucleotide, a key investigational medicine in our growing infectious diseases portfolio.
-
Moderna’s COVID-19 vaccine shows promise in older adults
Neutralising antibodies, while not definite proof that a vaccine is effective, are important in early clinical development and are an indicator of efficacy against infectious diseases like COVID-19. ... The clinical development of mRNA-1273 is being
-
Translate Bio, Sanofi's COVID-19 vaccine proves promising in animal studies
The expanded deal also builds upon Sanofi’s initial agreement with Translate, signed in 2018, to partner on mRNA vaccines for infectious diseases. ... current and future infectious diseases.”.
-
Roche, Regeneron partner on COVID-19 antibody cocktail
19. In July, Regeneron advanced the antibody cocktail, REGN-COV2, into a phase 3 trial being jointly run by the US National Institute of Allergy and Infectious Diseases (NIAID).
-
Speed kills
Infectious Diseases, told a Senate hearing on the pandemic in late June.
More from news
Approximately 4 fully matching, plus 195 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
I don’t think the ongoing trials will tell us a lot,” said H Clifford Lane, clinical director at the National Institutes of Allergy and Infectious Diseases (NIAID). ... IL-6 is a type of cytokine that plays an important role in immune response and is
-
We’ll need more than a spoonful of sugar to counter vaccine hesitancy
It is, therefore, critical that action is taken to stop the re-emergence of dangerous infectious diseases.
-
Biotech profile: Tom Evans, CEO, Vaccitech.
He moved to the University of Rochester as Associate Professor for 5 years, before becoming Infectious Diseases Division Chief and tenured full Professor at the University of California, Davis. ... In 2005, he joined the Novartis Institutes for
-
The threat of antimicrobial resistance
A study recently reported in The Lancet Infectious Diseases found that antibiotics are now failing to work in a fifth of patients who suffer an infection after hospital surgery.
-
Deal Watch February 2016
Alere has annual sales of approximately $2.5bn from a portfolio of point-of-care products in areas including cardiometabolic, infectious diseases such as HIV, malaria, syphilis, E. ... Pronutria's focus is on the development of therapeutics and
More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.
Latest appointments
-
Evoke KYNE promotes Dante DelVecchio to senior VP
In his new role, he will become a member of the firm’s senior management team, and will continue to oversee key client engagements in infectious diseases, vaccines and immuno-oncology.
-
New faces at HCA, P\S\L Group and Health Unlimited
Over her 15-year career, Peck has worked across a range of healthcare communications areas, including oncology, dermatology, infectious diseases and more.
-
New hires at Bayer, Eisai and Accord Healthcare
Most recently, she held the position of vice president of M&A operations and divestitures and led the infectious diseases and vaccines business development. ... She joins Eisai from Merck, where she served as executive director, clinical quality assurance
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
and infectious diseases.
-
Nabriva Therapeutics appoints chief medical officer
Commenting on the appointment, Dr Colin Broom, chief executive officer of Nabriva, said: “Jennifer has broad expertise in infectious diseases and internal medicine with extensive experience in both clinical development and
More from appointments
Approximately 0 fully matching, plus 38 partially matching documents found.
Latest from PMHub
-
Understanding COVID-19 and varying responses across the globe
The Coalition for Epidemic Preparedness Innovation (CEPI), a global alliance financing and coordinating the development of vaccines against emerging infectious diseases, launched in 2017 and is needed now more than ever. ... These three factors all aid
-
Speakers Announced: Maintaining Market Access Continuity through a Global Pandemic Webinar
Professor Jean Paul Stahl, Professor of Infectious Diseases, University Hospital, Grenoble, France. ... Former President of the French Infectious Diseases Society. Edmund Pezalla, Former Vice President, National Medical Director, Pharmaceutical Policy
-
Lucid Group adds more magic to the mix with four new hires
Betty has worked on a wide variety of medical education initiatives in various therapeutic areas including immuno-oncology, infectious diseases, transplantation and multiple sclerosis. ... Katherine has a background in oncology, neurology, metabolic
-
Antibiotic resistance: The silent pandemic
In a globalised world, infectious diseases can travel long distances in relatively short periods of time, making the problem of resistance one that is relevant to all seven billion of us
-
UK vs US: what makes a successful immunisation programme?
Emily Macdonald calls on her experience as a public health nurse specialising in the prevention of infectious disease in both the US and UK, to explore the differences between immunisation programmes ... We understand infectious diseases so well that we
More from PMHub
Approximately 1 fully matching, plus 12 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- How COVID-19 is accelerating the threat of antimicrobial resistance
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Keytruda doubles five-year survival rate in NSCLC
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
